OCUL · ISSUER CIK 1393434
OCULAR THERAPEUTIX, INC
Between Aug 1, 2026 and Oct 29, 2026, 6 OCULAR THERAPEUTIX, INC insiders reported $0.00 of open-market purchases and $568K of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 7 of 8 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$568KInsider selling
−$568KNet open-market
Oct 13, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 202617:01 | Oct 8, 2026 | OCUL | Chief Legal Officer | S · Sell10b5-1Late 5d | $7.29 | −11,984 | 140,484 | -8% | −$87K | ||
| Oct 6, 202616:44 | Oct 2, 2026 | OCUL | Chief Development Officer | S · Sell10b5-1 | $7.05 | −9,990 | 254,388 | -4% | −$70K | ||
| Oct 6, 202616:43 | Oct 2, 2026 | OCUL | Chief Scientific Officer | S · Sell10b5-1 | $7.05 | −10,869 | 307,457 | -3% | −$77K | ||
| Sep 2, 202616:01 | Aug 31, 2026 | OCUL | Chief Operating Officer | S · Sell | $10.24 | −1,099 | 366,529 | -0% | −$11K | ||
| Aug 26, 202617:59 | Aug 24, 2026 | OCUL | Chief Development Officer | S · Sell10b5-1 | $10.77 | −3,035 | 264,378 | -1% | −$33K | ||
| Aug 26, 202617:58 | Aug 24, 2026 | OCUL | Chief Strategy Officer | S · Sell10b5-1 | $10.78 | −1,897 | 326,898 | -1% | −$20K | ||
| Aug 26, 202617:57 | Aug 24, 2026 | OCUL | Chief Scientific Officer | S · Sell10b5-1 | $10.78 | −3,296 | 318,326 | -1% | −$36K | ||
| Aug 26, 202617:56 | Aug 24, 2026 | OCUL | See Remarks, Director | S · Sell10b5-1 | $10.77 | −21,649 | 2,525,429 | -1% | −$233K | ||
| Aug 26, 202617:56 | Aug 25, 2026 | OCUL | See Remarks, Director | G · Gift10b5-1 | — | −50,092 | 0 | -100% | — | ||
| Aug 26, 202617:56 | Aug 25, 2026 | OCUL | See Remarks, Director | G · Gift10b5-1 | — | +50,092 | 744,903 | +7% | — |